{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:35:33Z","timestamp":1791171333555,"version":"4.1.0"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,5,1]]},"abstract":"<jats:p> PURPOSE: Benchmark analysis of patients with chronic myeloid leukemia (CML) alive for more than 10 years after allogeneic bone marrow transplantation (BMT) including data on disease status, bone marrow reserve, long-term complications, and quality of life (QOL). <\/jats:p><jats:p> PATIENTS AND METHODS: Eighty-nine patients (46 in first chronic phase, 43 in advanced phase) received an allogeneic BMT for CML during the study period. Medical outcomes and QOL of patients were analyzed retrospectively. <\/jats:p><jats:p> RESULTS: Twenty-eight (31.5%) of 89 patients were alive at 10 years and included in this analysis. Thirteen (46.4%) of 28 long-term survivors never relapsed. Fifteen patients relapsed between 0.5 and 16 years after transplantation. Ten patients showed a hematologic relapse and received salvage treatment. Five patients showed transient low levels of BCR-ABL\u2013positive cells by Southern blot with no subsequent hematologic relapse. One of the 28 patients died in blast crisis at 12 years. The most frequent long-term complications were chronic graft-versus-host disease, osteoporosis, and cataracts. Frequency of clonogenic progenitors remained persistently decreased. QOL assessment yielded lower scores in physical performance as compared with an age-matched normative population, whereas social functioning was equivalent. A high degree of satisfaction was noted with interpersonal relationships. <\/jats:p><jats:p> CONCLUSION: Patients with CML surviving their BMT long term do well in terms of medical outcomes. A constant rate of relapse was noted, with a high salvage rate of affected patients, suggesting the need for lifelong monitoring. QOL is perceived as good, particularly as related to social functioning; however, it is inferior to a normative population with regard to physical performance. <\/jats:p>","DOI":"10.1200\/jco.2002.06.077","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T13:13:48Z","timestamp":1027775628000},"page":"2334-2343","source":"Crossref","is-referenced-by-count":120,"title":["Long-Term Medical Outcomes and Quality-of-Life Assessment of Patients With Chronic Myeloid Leukemia Followed at Least 10 Years After Allogeneic Bone Marrow Transplantation"],"prefix":"10.1200","volume":"20","author":[{"given":"T.L.","family":"Kiss","sequence":"first","affiliation":[{"name":"From the Bone Marrow Transplant Service, Department of Medical Oncology and Hematology, Princess Margaret Hospital\/University Health Network, and the Population Health Sciences Research Institute, The Hospital for Sick Children and Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Abdolell","sequence":"additional","affiliation":[{"name":"From the Bone Marrow Transplant Service, Department of Medical Oncology and Hematology, Princess Margaret Hospital\/University Health Network, and the Population Health Sciences Research Institute, The Hospital for Sick Children and Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Jamal","sequence":"additional","affiliation":[{"name":"From the Bone Marrow Transplant Service, Department of Medical Oncology and Hematology, Princess Margaret Hospital\/University Health Network, and the Population Health Sciences Research Institute, The Hospital for Sick Children and Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Minden","sequence":"additional","affiliation":[{"name":"From the Bone Marrow Transplant Service, Department of Medical Oncology and Hematology, Princess Margaret Hospital\/University Health Network, and the Population Health Sciences Research Institute, The Hospital for Sick Children and Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Lipton","sequence":"additional","affiliation":[{"name":"From the Bone Marrow Transplant Service, Department of Medical Oncology and Hematology, Princess Margaret Hospital\/University Health Network, and the Population Health Sciences Research Institute, The Hospital for Sick Children and Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.A.","family":"Messner","sequence":"additional","affiliation":[{"name":"From the Bone Marrow Transplant Service, Department of Medical Oncology and Hematology, Princess Margaret Hospital\/University Health Network, and the Population Health Sciences Research Institute, The Hospital for Sick Children and Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-107618","unstructured":"Appelbaum  FR,   Clift  R,   Radich  J,  et al:  Bone marrow transplantation for chronic myelogenous leukemia.  Semin Oncol 22:  405,1995-411,"},{"key":"R2-107618","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.8.3069.bloodjournal8783069"},{"key":"R3-107618","unstructured":"Horowitz  MM,   Rowlings  PA,   Passweg  JR:   Allogeneic bone marrow transplantation for CML:  A report from the International Bone Marrow Transplant Registry.   Bone Marrow Transplant 17:  S5,1996-S6,     (suppl 3)"},{"key":"R4-107618","doi-asserted-by":"crossref","unstructured":"Moreb  J,   Johnston  T,   Kubilis  P,  et al:  Improved survival of patients with chronic myelogenous leukemia undergoing allo-geneic bone marrow transplantation.  Am J Hematol 5:  304,1995-306,","DOI":"10.1002\/ajh.2830500416"},{"key":"R5-107618","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.8.2263.bloodjournal8582263"},{"key":"R6-107618","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701031"},{"key":"R7-107618","doi-asserted-by":"crossref","unstructured":"Gratwohl  A,   Hermans  J,   Niederwieser  D,  et al:  Bone marrow transplantation for chronic myeloid leukemia:  Long term results.   Bone Marrow Transplant 12:  509,1993-516,","DOI":"10.1007\/978-3-642-77083-8_33"},{"key":"R8-107618","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700933"},{"key":"R9-107618","unstructured":"Gratwohl  A,   Hermans  J:   Allogeneic bone marrow transplantation for chronic myeloid leukemia.  Bone Marrow Transplant 17:  S7,1996-S9,     (suppl 3)"},{"key":"R10-107618","unstructured":"Clift  RA,   Storb  R:   Marrow transplantation for CML:  The Seattle experience.   Bone Marrow Transplant 17:  S1,1996-S3,     (suppl 3)"},{"key":"R11-107618","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700672"},{"key":"R12-107618","doi-asserted-by":"publisher","DOI":"10.1007\/BF00704432"},{"key":"R13-107618","unstructured":"Prieto  JM,   Saez  R,   Carreras  E,  et al:  Physical and psychosocial functioning of 117 survivors of bone marrow transplantation.  Bone Marrow Transplant 17:  1133,1996-1142,"},{"key":"R14-107618","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1994.75.1.323"},{"key":"R15-107618","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050407"},{"key":"R16-107618","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701115"},{"key":"R17-107618","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700806"},{"key":"R18-107618","unstructured":"Molassiotis  A,   van den Akker  OB,   Milligan  DW,  et al:  Quality of life in long term survivors of marrow transplantation:  Comparison with a matched group receiving maintenance chemotherapy.   Bone Marrow Transplant 17:  249,1996-258,"},{"key":"R19-107618","doi-asserted-by":"publisher","DOI":"10.1016\/0277-9536(94)00153-K"},{"key":"R20-107618","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"R21-107618","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199303000-00006"},{"key":"R22-107618","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199401000-00004"},{"key":"R24-107618","unstructured":"Fyles  GM,   Messner  HA,   Lockwood  G,  et al:  Long term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500cGy delivered with a high dose rate.  Bone Marrow Transplant 8:  453,1991-463,"},{"key":"R25-107618","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198903303201303"},{"key":"R26-107618","doi-asserted-by":"crossref","unstructured":"Storb  R,   Deeg  HJ,   Whitehead  J:   Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.  N Engl J Med 314:  729,1984-735,","DOI":"10.1056\/NEJM198603203141201"},{"key":"R27-107618","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.5.1425.1425"},{"key":"R28-107618","unstructured":"Xu  WM,   Piao  XH,   Addy  L,  et al:  Minimal residual disease in bone marrow transplant recipients with chronic myeloid leukemia.  Bone Marrow Transplant 14:  299,1994-306,"},{"key":"R29-107618","doi-asserted-by":"crossref","unstructured":"Baker  F,   Curbow  B,   Wingard  JR:   Development of the satisfaction with life domains scale for cancer.  J Psychosoc Oncol 10:  75,1992-90,","DOI":"10.1300\/J077V10N03_05"},{"key":"R30-107618","doi-asserted-by":"publisher","DOI":"10.1016\/0277-9536(91)90149-7"},{"key":"R32-107618","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R33-107618","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909058476"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.06.077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:55:59Z","timestamp":1653515759000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.06.077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,1]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,5,1]]}},"alternative-id":["10.1200\/JCO.2002.06.077"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.06.077","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,1]]}}}